The earnings call highlighted strong performance in the growth portfolio and raised revenue guidance, demonstrating confidence in the company's strategic direction. However, unmet expectations in certain Phase III trials and the decline of the legacy portfolio were noted as challenges.

Company Guidance -

Q3 2025

During Bristol-Myers Squibb's second quarter 2025 earnings call, the company announced strong financial performance, with total revenue reaching approximately $12.3 billion, representing a 17% year-over-year increase in sales driven by demand across key brands. The company raised its full-year revenue guidance by $700 million, projecting between $46.5 billion and $47.5 billion. Opdivo sales reached $2.6 billion, and the launch of Qvantig in the U.S. generated $30 million in sales. The growth portfolio, including products like Breyanzi and Camzyos, contributed significantly. The company also highlighted strategic partnerships with BioNTech and Philochem, raising top-line and bottom-line guidance, excluding acquired IP R&D charges. Gross margins were approximately 73% for the quarter, and they maintained a strong cash position with $13.9 billion in cash and cash equivalents. The company emphasized its commitment to strategic capital deployment and productivity initiatives as it continues to focus on long-term sustainable growth.

Strong Growth Portfolio Performance

Sales increased 17% year-over-year, driven by demand across key brands such as Opdivo, Breyanzi, Reblozyl, and Camzyos.

Rising Revenue Guidance

Full-year reported revenue guidance increased by $700 million, now projected between $46.5 billion to $47.5 billion.

Regulatory Progress

Secured approval for Opdivo in neoadjuvant lung cancer and Qvantig across multiple solid tumor indications in Europe. The FDA streamlined patient monitoring for cell therapies in the U.S.

Strategic Partnerships

Partnerships with BioNTech and Philochem to expand immuno-oncology and radiopharmaceutical capabilities, respectively.

Camzyos Growth

Camzyos sales grew 86% due to robust demand, with $260 million in global sales.

Bristol-Myers Squibb (BMY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BMY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	1.69 / -	1.8	―	―	―
Aug 01, 2025	2025 (Q2)	1.09 / 1.46	2.07	-29.47% (-0.61)
Apr 24, 2025	2025 (Q1)	1.50 / 1.80	-4.4	140.91% (+6.20)
Feb 06, 2025	2024 (Q4)	1.46 / 1.67	1.7	-1.76% (-0.03)
Oct 31, 2024	2024 (Q3)	1.49 / 1.80	2	-10.00% (-0.20)
Jul 26, 2024	2024 (Q2)	1.62 / 2.07	1.75	18.29% (+0.32)
Apr 25, 2024	2024 (Q1)	-4.41 / -4.40	2.05	-314.63% (-6.45)
Feb 02, 2024	2023 (Q4)	1.55 / 1.70	1.82	-6.59% (-0.12)
Oct 26, 2023	2023 (Q3)	1.76 / 2.00	1.99	0.50% (+0.01)
Jul 27, 2023	2023 (Q2)	1.96 / 1.75	1.93	-9.33% (-0.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BMY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 01, 2025	$43.31	$44.23	+2.12%
Apr 24, 2025	$47.90	$48.06	+0.33%
Feb 06, 2025	$58.30	$56.06	-3.84%
Oct 31, 2024	$50.86	$53.86	+5.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.